Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Epizyme to host conference call » 17:53
02/25/21
02/25
17:53
02/25/21
17:53
EPZM

Epizyme

$9.66 /

-0.55 (-5.39%)

Conference call to…

Conference call to discuss the Company's corporate strategy, TAZVERIK developmental plans and recent advancements in the epigenetic pipeline will be held on March 2 at 10 am. Webcast Link

ShowHide Related Items >><<
EPZM Epizyme
$9.66 /

-0.55 (-5.39%)

EPZM Epizyme
$9.66 /

-0.55 (-5.39%)

02/25/21 Morgan Stanley
Epizyme downgraded to Equal Weight on Tazverik challenges at Morgan Stanley
02/25/21 Morgan Stanley
Epizyme downgraded to Equal Weight from Overweight at Morgan Stanley
02/24/21 Citi
Epizyme price target lowered to $27 from $35 at Citi
12/21/20 Jefferies
Epizyme downgraded to Hold at Jefferies on lower than consensus Tazverik view
EPZM Epizyme
$9.66 /

-0.55 (-5.39%)

EPZM Epizyme
$9.66 /

-0.55 (-5.39%)

EPZM Epizyme
$9.66 /

-0.55 (-5.39%)

Downgrade
Epizyme downgraded to Equal Weight on Tazverik challenges at Morgan Stanley » 07:10
02/25/21
02/25
07:10
02/25/21
07:10
EPZM

Epizyme

$10.21 /

-0.19 (-1.83%)

As previously reported,…

As previously reported, Morgan Stanley analyst David Lebowitz downgraded Epizyme to Equal Weight from Overweight with a price target of $14, down from $27, following Q4 results that he said illustrate how the pandemic continues to weigh on the launch of Tazverik for the treatment of follicular lymphoma, or FL. He expects 2021 to continue to be a challenging launch environment, leading him to lower his Tazverik sales expectations and downgrade the stock, Lebowitz tells investors in a research note.

ShowHide Related Items >><<
EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

02/25/21 Morgan Stanley
Epizyme downgraded to Equal Weight from Overweight at Morgan Stanley
02/24/21 Citi
Epizyme price target lowered to $27 from $35 at Citi
12/21/20 Jefferies
Epizyme downgraded to Hold at Jefferies on lower than consensus Tazverik view
12/21/20 Jefferies
Epizyme downgraded to Hold from Buy at Jefferies
EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

Downgrade
Epizyme downgraded to Equal Weight from Overweight at Morgan Stanley » 05:27
02/25/21
02/25
05:27
02/25/21
05:27
EPZM

Epizyme

$10.21 /

-0.19 (-1.83%)

Morgan Stanley analyst…

Morgan Stanley analyst David Lebowitz downgraded Epizyme to Equal Weight from Overweight with a $14 price target.

ShowHide Related Items >><<
EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

02/24/21 Citi
Epizyme price target lowered to $27 from $35 at Citi
12/21/20 Jefferies
Epizyme downgraded to Hold at Jefferies on lower than consensus Tazverik view
12/21/20 Jefferies
Epizyme downgraded to Hold from Buy at Jefferies
11/09/20 Barclays
Epizyme price target lowered to $18 from $33 at Barclays
EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

EPZM Epizyme
$10.21 /

-0.19 (-1.83%)

Wednesday
Recommendations
Epizyme price target lowered to $27 from $35 at Citi » 06:36
02/24/21
02/24
06:36
02/24/21
06:36
EPZM

Epizyme

$10.40 /

-0.3 (-2.80%)

Citi analyst Mohit Bansal…

Citi analyst Mohit Bansal lowered the firm's price target on Epizyme to $27 from $35 and keeps a Buy rating on the shares. While investor expectations for Tazverik Q4 numbers were low at $6M-$7M, the actual sales of $4.5M was disappointing, Bansal tells investors in a research note. The analyst lowered near-term sales estimates for Tazverik as he's now less confident in the launch trajectory. However, Bansal remains optimistic about the long-term value and potential of the asset.

ShowHide Related Items >><<
EPZM Epizyme
$10.40 /

-0.3 (-2.80%)

EPZM Epizyme
$10.40 /

-0.3 (-2.80%)

12/21/20 Jefferies
Epizyme downgraded to Hold at Jefferies on lower than consensus Tazverik view
12/21/20 Jefferies
Epizyme downgraded to Hold from Buy at Jefferies
11/09/20 Barclays
Epizyme price target lowered to $18 from $33 at Barclays
10/05/20 Citi
Citi highlights Epizyme, Karuna as potential targets after MyoKardia takeover
EPZM Epizyme
$10.40 /

-0.3 (-2.80%)

EPZM Epizyme
$10.40 /

-0.3 (-2.80%)

EPZM Epizyme
$10.40 /

-0.3 (-2.80%)

Over a week ago
Hot Stocks
Epizyme sees FY21 non-GAAP adjusted operating expenses $235M-$255M » 06:43
02/23/21
02/23
06:43
02/23/21
06:43
EPZM

Epizyme

$10.70 /

+0.1 (+0.94%)

Based on its current…

Based on its current operating plans, Epizyme expects its current cash runway to extend into 2023.

ShowHide Related Items >><<
EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

12/21/20 Jefferies
Epizyme downgraded to Hold at Jefferies on lower than consensus Tazverik view
12/21/20 Jefferies
Epizyme downgraded to Hold from Buy at Jefferies
11/09/20 Barclays
Epizyme price target lowered to $18 from $33 at Barclays
10/05/20 Citi
Citi highlights Epizyme, Karuna as potential targets after MyoKardia takeover
EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

Earnings
Epizyme reports Q4 EPS (65c), consensus (58c) » 06:42
02/23/21
02/23
06:42
02/23/21
06:42
EPZM

Epizyme

$10.70 /

+0.1 (+0.94%)

Reports Q4 revenue $8.4M,…

Reports Q4 revenue $8.4M, consensus $6.19M. "Epizyme cemented its position as a leader in epigenetics in 2020, with back-to-back accelerated approvals for TAZVERIK, the first and only FDA-approved EZH2 inhibitor. Following the approvals, we quickly reached epithelioid sarcoma and follicular lymphoma patients in need, adapting our physician and patient outreach efforts to meet the unique challenges presented by the evolving COVID-19 pandemic," said Robert Bazemore, President and CEO. "While the resurgence of COVID-19 cases in the fourth quarter extended many of these challenges, the adoption of TAZVERIK in both ES and FL continued to expand, with net revenue increasing 31% in the fourth quarter from the third quarter. Importantly, our sales and medical affairs teams continue to make progress reaching and educating physicians, reflected in the more than 50% increase in new accounts prescribing TAZVERIK during the fourth quarter. In addition to launch execution, we are encouraged by our clinical progress throughout 2020, during which we achieved all trial milestones on or ahead of schedule. Armed with sufficient capital to support our planned commercial and clinical execution, we believe Epizyme is well-positioned for success in 2021 and beyond."

ShowHide Related Items >><<
EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

12/21/20 Jefferies
Epizyme downgraded to Hold at Jefferies on lower than consensus Tazverik view
12/21/20 Jefferies
Epizyme downgraded to Hold from Buy at Jefferies
11/09/20 Barclays
Epizyme price target lowered to $18 from $33 at Barclays
10/05/20 Citi
Citi highlights Epizyme, Karuna as potential targets after MyoKardia takeover
EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

EPZM Epizyme
$10.70 /

+0.1 (+0.94%)

Over a month ago
Periodicals
Epizyme could be 'vulnerable to an activist investor,' Insightia says » 10:00
01/20/21
01/20
10:00
01/20/21
10:00
EPZM

Epizyme

$11.80 /

+ (+0.00%)

Following a failure to…

Following a failure to commercialize its "promising oral cancer drug" due to the pandemic and a lack of corporate partnerships, Epizyme is "vulnerable to an activist investor that could push for a sale or at least seek partners with better industry relationships," said Insightia, contacts tell The Fly. Insightia is the owner of Activist Insight and Proxy Insight, which "provide a variety of shareholder activism, corporate governance, and shareholder voting data to a diverse range of clients around the world."

ShowHide Related Items >><<
EPZM Epizyme
$11.80 /

+ (+0.00%)

EPZM Epizyme
$11.80 /

+ (+0.00%)

12/21/20 Jefferies
Epizyme downgraded to Hold at Jefferies on lower than consensus Tazverik view
12/21/20 Jefferies
Epizyme downgraded to Hold from Buy at Jefferies
11/09/20 Barclays
Epizyme price target lowered to $18 from $33 at Barclays
10/05/20 Citi
Citi highlights Epizyme, Karuna as potential targets after MyoKardia takeover
EPZM Epizyme
$11.80 /

+ (+0.00%)

EPZM Epizyme
$11.80 /

+ (+0.00%)

Hot Stocks
Epizyme says Boehringer Ingelheim terminated collaboration agreement » 07:29
12/24/20
12/24
07:29
12/24/20
07:29
EPZM

Epizyme

$11.82 /

-0.19 (-1.58%)

In a regulatory filing…

In a regulatory filing last night, Epizyme reported that on December 21, the company received written notice from Boehringer Ingelheim International GmbH, or "BII," that BII has elected to terminate the collaboration agreement dated November 14, 2018, by and between the company and BII, as amended by Amendment No. 1, dated March 10, 2020, and Amendment No. 2, dated September 17, 2020. BII terminated the collaboration agreement without cause, and in accordance with the terms of the agreement, and the parties have agreed that the termination will be effective on January 31, 2021, Epizyme said. Under the collaboration agreement, the parties had agreed to discover, research, develop and commercialize small molecule compounds that are inhibitors of an undisclosed histone acetyltransferase target and an undisclosed helicase target in indications chosen by BII. As a result of the termination of the collaboration agreement, as of the termination date the licenses granted by the company to BII and the reciprocal licenses will terminate, BII will cease to accrue any financial obligations to the company and the company will be entitled to pursue the HAT target and helicase target programs in all fields worldwide without further obligation to BII, Epizyme added.

ShowHide Related Items >><<
EPZM Epizyme
$11.82 /

-0.19 (-1.58%)

EPZM Epizyme
$11.82 /

-0.19 (-1.58%)

12/21/20 Jefferies
Epizyme downgraded to Hold at Jefferies on lower than consensus Tazverik view
12/21/20 Jefferies
Epizyme downgraded to Hold from Buy at Jefferies
11/09/20 Barclays
Epizyme price target lowered to $18 from $33 at Barclays
10/05/20 Citi
Citi highlights Epizyme, Karuna as potential targets after MyoKardia takeover
EPZM Epizyme
$11.82 /

-0.19 (-1.58%)

EPZM Epizyme
$11.82 /

-0.19 (-1.58%)

Downgrade
Epizyme downgraded to Hold at Jefferies on lower than consensus Tazverik view » 08:15
12/21/20
12/21
08:15
12/21/20
08:15
EPZM

Epizyme

$12.41 /

-0.33 (-2.59%)

As previously reported,…

As previously reported, Jefferies analyst Michael Yee downgraded Epizyme to Hold from Buy with a price target of $14, down from $18. While the launch for Tazverik is progressing, given the logistical challenges of a launch during the pandemic as well as ASH COVID-19 pandemic guidelines that continue to recommend a "watchful waiting" approach to new therapies for indolent lymphomas, he is below consensus with his own view for 2021, Yee tells investors. For 2021, he forecasts sales for Tazverik of $53M, which Yee notes is about 30% below the consensus revenue forecast of $75M.

ShowHide Related Items >><<
EPZM Epizyme
$12.41 /

-0.33 (-2.59%)

EPZM Epizyme
$12.41 /

-0.33 (-2.59%)

12/21/20 Jefferies
Epizyme downgraded to Hold from Buy at Jefferies
11/09/20 Barclays
Epizyme price target lowered to $18 from $33 at Barclays
10/05/20 Citi
Citi highlights Epizyme, Karuna as potential targets after MyoKardia takeover
06/19/20 Citi
Epizyme should be bought on any confusion over label, at Citi
EPZM Epizyme
$12.41 /

-0.33 (-2.59%)

EPZM Epizyme
$12.41 /

-0.33 (-2.59%)

Downgrade
Epizyme downgraded to Hold from Buy at Jefferies » 04:50
12/21/20
12/21
04:50
12/21/20
04:50
EPZM

Epizyme

$12.41 /

-0.33 (-2.59%)

Jefferies analyst Michael…

Jefferies analyst Michael Yee downgraded Epizyme to Hold from Buy with a $14 price target.

ShowHide Related Items >><<
EPZM Epizyme
$12.41 /

-0.33 (-2.59%)

EPZM Epizyme
$12.41 /

-0.33 (-2.59%)

11/09/20 Barclays
Epizyme price target lowered to $18 from $33 at Barclays
10/05/20 Citi
Citi highlights Epizyme, Karuna as potential targets after MyoKardia takeover
06/19/20 Citi
Epizyme should be bought on any confusion over label, at Citi
06/18/20 Jefferies
Jefferies sees broad approval for Epizyme's Taz as 'fundamental positive'
EPZM Epizyme
$12.41 /

-0.33 (-2.59%)

EPZM Epizyme
$12.41 /

-0.33 (-2.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.